NeuroNode US Distribution Deal: Can Control Bionics Scale Amid Gradual Ramp-Up?
Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.
- Two-year US distribution agreement signed with PRC-Saltillo
- PRC-Saltillo trained sales staff and conducted NeuroNode trials in 2025
- NeuroNode complements existing AAC solutions by detecting subtle muscle signals
- Agreement supports Control Bionics’ strategic priority for US market expansion
- Confidential commercial terms with gradual sales ramp-up expected
Strategic US Partnership Formalised
Control Bionics Limited (ASX, CBL) has taken a significant step in expanding its footprint in the United States by signing a distribution agreement with PRC-Saltillo, a globally recognised leader in Augmentative and Alternative Communication (AAC) solutions. This two-year deal positions PRC-Saltillo as the official distributor of Control Bionics’ NeuroNode technology across the US market.
Throughout 2025, PRC-Saltillo has already been actively engaged with the NeuroNode, training sales personnel and conducting device trials and demonstrations. Notably, insurance funding for NeuroNode access has been approved for PRC clients, indicating early market acceptance and paving the way for smoother commercialisation.
Enhancing Communication Through Innovation
The NeuroNode device leverages surface electromyography (sEMG) to detect minute muscle activations, enabling individuals with complex communication needs to control speech and computer functions where traditional access methods fall short. By integrating with PRC-Saltillo’s existing AAC offerings, the NeuroNode adds a valuable new access modality, potentially improving communication speed and reducing user fatigue.
Control Bionics brings over two decades of expertise in sEMG-based assistive technology, while PRC-Saltillo’s established presence and clinical support infrastructure in the AAC market provide a strong platform for scaling NeuroNode adoption.
Growth Prospects and Strategic Alignment
Jeremy Steele, CEO of Control Bionics, emphasised the importance of this partnership as a foundation for sustainable growth in the US. While sales are expected to ramp up gradually as PRC-Saltillo integrates the NeuroNode into its sales channels and continues training, the agreement aligns with Control Bionics’ strategic priority of expanding NeuroNode sales through key distribution relationships.
This deal also complements Control Bionics’ recent distribution partnership with Tobii Dynavox, further solidifying its position in the assistive technology sector. The company’s ongoing innovation, including the development of the miniaturised NeuroStrip device, signals potential entry into adjacent markets such as health diagnostics and sports performance.
Looking Ahead
As Control Bionics and PRC-Saltillo deepen their collaboration, the NeuroNode’s enhanced accessibility in the US could mark a turning point for individuals reliant on AAC technologies. The coming months will be critical to observe how quickly the market embraces this novel access method and how it impacts the broader assistive technology landscape.
Bottom Line?
This US distribution deal sets the stage for Control Bionics to accelerate NeuroNode adoption, but market traction will depend on execution and ongoing partner engagement.
Questions in the middle?
- How quickly will PRC-Saltillo scale NeuroNode sales across the US?
- What financial impact will this distribution agreement have on Control Bionics’ revenue?
- Could the NeuroStrip device open new markets beyond communication aids?
